HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a ...
Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in ...
One of these assets is catalyst-driven; the other isn't.
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Phase 3 top-line results from its EMANATE trial evaluating setmelanotide in four heterozygous genetic cohorts linked to MC4R pathway dysfunction, with com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results